Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Dupixent approved in the US as the first-ever biologic medicine for patients ...
Dupixent approved by FDA as first biologic for COPD patients with eosinophilic phenotype, based on phase 3 studies showing significant reduction in exacerbations, improved lung function, and quality of life.
Dupixent® (dupilumab) Approved in the U.S. as the
FDA approves Dupixent for adults with inadequately controlled COPD and an eosinophilic phenotype, based on Phase 3 trials showing significant reduction in exacerbations, improved lung function, and quality of life.
First-Ever Biologic Approved for COPD
The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with inadequately controlled COPD with an eosinophilic phenotype. Dupilumab, an IL-4 and IL-13 pathway inhibitor, demonstrated a reduction in annual exacerbations in phase III trials BOREAS and NOTUS. It also improved quality of life and lung function. Common adverse events included viral infection, headache, and nasopharyngitis.
AbbVie's Parkinson's Drug Tavapadon: A Market Perform Rating Amidst Competitive
Leerink Partners' David Risinger maintains a Hold rating on AbbVie (ABBV) stock, citing positive Phase 3 tavapadon trial results but cautious about sales projections, remaining trials, and market competition.
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients
Dupixent approved by FDA as add-on treatment for adults with inadequately controlled COPD and eosinophilic phenotype, based on Phase 3 trials showing significant reduction in exacerbations, improvements in lung function and quality of life.
Dupixent Approved in the US as the First-Ever Biologic Medicine for Patients with COPD
The FDA approves Dupixent as the first biologic for COPD patients with an eosinophilic phenotype, based on phase 3 studies showing reduced exacerbations and improved lung function.
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
FDA approves Sanofi and Regeneron’s Dupixent for chronic lung disease, expected to boost sales to over $21 billion by 2030.
Dupixent approved in China as the first-ever
Dupixent approved in China for COPD, based on phase 3 studies showing reduced exacerbations, improved lung function, and quality of life. COPD is a priority in China's Healthy China 2030 plan.
Sanofi/Regeneron's Dupixent set to dominate COPD biologics market following FDA approval
FDA approves Sanofi and Regeneron's Dupixent for uncontrolled COPD, showing significant reduction in exacerbations and improved lung function. Dupixent expected to lead COPD biologics market with projected sales of $6.57bn by 2033.
FDA approves dupilumab for COPD with type 2 inflammation
FDA approves dupilumab for treating poorly controlled COPD with type 2 inflammation, based on BOREAS and NOTUS studies showing reduced exacerbation rates and improved lung function.
© Copyright 2024. All Rights Reserved by MedPath